The normalization of the Covid virus does not weigh down bioMérieux's results.
Last year, the in vitro diagnostics specialist more than offset the fall in sales of its Covid tests.
Its turnover increased by 2.4%, and even by 6.6% at constant exchange rate, to 3.6 billion euros, above its forecasts.
“
The Covid years were special, exceptional years.
Luckily for everyone, we got through it.
But despite the drop in sales linked to this virus, bioMérieux is today stronger than before
: our turnover is exactly 1 billion higher than in 2019, and our operating profit has increased by 50
%, 400 to 600
million euros.
We have become the 6th largest player in the world
,”
says Pierre Boulud, the new general director of the laboratory.
With Covid, doctors and patients have acquired a new reflex: that of testing to identify the virus in question.
“
Patients are less satisfied with hearing…
This article is reserved for subscribers.
You have 80% left to discover.
Flash sale
€4.49/month for 12 months
I ENJOY IT
Already subscribed?
Log in